Peak6 Investments LLC Bluebird Bio, Inc. Call Options Transaction History

Peak6 Investments LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $52,500 - $103,460	14,000 New	14,000 $89,000
Q3 2021 Nov 12, 2021	SELL	$11.24 - $21.0 $260,768 - $487,200	-23,200 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$18.04 - $22.09 $1.52 Million - $1.86 Million	-84,300 Reduced 78.42%	23,200 $742,000
Q4 2020 Feb 12, 2021	BUY	$27.5 - $37.92 $506,000 - $697,728	18,400 Added 20.65%	107,500 $4.65 Million
Q3 2020 Nov 13, 2020	BUY	$34.44 - $43.75 $2.45 Million - $3.12 Million	71,200 Added 397.77%	89,100 $3.11 Million
Q2 2020 Aug 14, 2020	SELL	$27.12 - $45.97 $108,480 - $183,880	-4,000 Reduced 18.26%	17,900 $1.09 Million
Q1 2020 May 14, 2020	SELL	$26.16 - $63.5 $685,392 - $1.66 Million	-26,200 Reduced 54.47%	21,900 $1.01 Million
Q4 2019 Feb 13, 2020	BUY	$46.96 - $61.67 $211,320 - $277,515	4,500 Added 10.32%	48,100 $4.22 Million
Q3 2019 Nov 08, 2019	BUY	$59.47 - $93.1 $2.58 Million - $4.04 Million	43,400 Added 21700.0%	43,600 $4 Million
Q2 2019 Aug 14, 2019	SELL	$75.84 - $105.21 $1.12 Million - $1.56 Million	-14,800 Reduced 98.67%	200 $25,000
Q3 2018 Nov 13, 2018	BUY	$88.86 - $117.49 $1.33 Million - $1.76 Million	15,000 New	15,000 $2.19 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $29.3M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Peak6 Investments LLC with notifications on news.